People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $85.4M | $3.0B | 2016 |
MATTHEW W. KORENBERG at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MATTHEW W. KORENBERG on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew W. Foehr | 1 | 4 |
| John L. Higgins | 1 | 2 |
| JOHN M. LAMATTINA | 1 | 1 |
| TODD S. DAVIS | 1 | 1 |
| SUNIL M. PATEL | 1 | 1 |
| JOHN S. KOZARICH | 1 | 1 |
| DAVID M. KNOTT | 1 | 1 |
| JASON S. ARYEH | 1 | 1 |
| CHARLES S. BERKMAN | 1 | 1 |
| STEPHEN M. SABBA | 1 | 1 |
| MELANIE S. HERMAN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.